SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alfacell (ACEL)
ACEL 11.64+1.7%Jan 15 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Jenco who wrote (1423)6/27/1998 1:06:00 AM
From: Gil Kempenich  Read Replies (1) of 1533
 
My recollection is as follows:
1) Completion of data accrual - end of August
2) Analysis follows
3) Pre-NDA meeting with FDA - around September/October
4) If FDA approves proceeding, NDA will be filed by year-end
5) Approval by mid-1999 (but could be earlier, as you suggested, John.

I suspect enhanced interest to begin around Sept timeframe - as soon as results of analysis are divulged - this could be a paper, or a presentation at a bio or medical meeting - what is deemed most appropriate and timely at that point.

Gil
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News